Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group. Johnson KP, et al. Among authors: goldstein j. Neurology. 2001 Dec;57(12 Suppl 5):S16-24. Neurology. 2001. PMID: 11902590 No abstract available.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Johnson KP, et al. Among authors: goldstein j. Neurology. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268. Neurology. 1995. PMID: 7617181 Clinical Trial.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Johnson KP, et al. Among authors: goldstein j. Neurology. 1998 Mar;50(3):701-8. doi: 10.1212/wnl.50.3.701. Neurology. 1998. PMID: 9521260 Clinical Trial.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group. Johnson KP, et al. Among authors: goldstein j. Neurology. 2001 Dec;57(12 Suppl 5):S46-53. Neurology. 2001. PMID: 11902595 No abstract available.
Subacute cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with antibodies to voltage-gated calcium channels: differential effect of immunosuppressive therapy on central and peripheral defects.
Goldstein JM, Waxman SG, Vollmer TL, Lang B, Johnston I, Newsom-Davis J. Goldstein JM, et al. J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1138-9. doi: 10.1136/jnnp.57.9.1138. J Neurol Neurosurg Psychiatry. 1994. PMID: 8089692 Free PMC article. No abstract available.
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.
Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J; Northeast ALS Consortium. Cudkowicz ME, et al. Among authors: goldstein j. Neurology. 2003 Aug 26;61(4):456-64. doi: 10.1212/wnl.61.4.456. Neurology. 2003. PMID: 12939417 Clinical Trial.
Substructure-Specific Antibodies Against Fentanyl Derivatives.
Chapman A, Xu M, Schroeder M, Goldstein JM, Chida A, Lee JR, Tang X, Wharton RE, Finn MG. Chapman A, et al. Among authors: goldstein jm. ACS Nano. 2025 Jan 10. doi: 10.1021/acsnano.4c14369. Online ahead of print. ACS Nano. 2025. PMID: 39792034
Cross-modal contrastive learning for unified placenta analysis using photographs.
Pan Y, Mehta M, Goldstein JA, Ngonzi J, Bebell LM, Roberts DJ, Carreon CK, Gallagher K, Walker RE, Gernand AD, Wang JZ. Pan Y, et al. Among authors: goldstein ja. Patterns (N Y). 2024 Nov 19;5(12):101097. doi: 10.1016/j.patter.2024.101097. eCollection 2024 Dec 13. Patterns (N Y). 2024. PMID: 39776848 Free PMC article.
4,274 results